Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 9, 2004, Pages 3552-3555

  Gonzalez, Luis M F ^a   Brindeiro, Rodrigo M ^a   Aguiar, Renato S ^a   Pereira, Helena S ^a   Abreu, Celina M ^a   Soares, Marcelo A ^a   Tanuri, Amilcar ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS ENZYME;

ANTIBIOTIC RESISTANCE; ARTICLE; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 4344641898     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.9.3552-3555.2004     Document Type: Article

References (20)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Ariyoshi, K., M. Matsuda, H. Miura, S. Tateishi, K. Yamada, and W. Sugiura. 2003. Patterns of point mutations associated with antiretroviral drug treatment failure in CRFO1_AE (subtype E) infection differ from subtype B infection. S. Acquir. Immune Defic. Syndr. 33:336-342.
3. Cane, P. A., A. de Ruiter, P. Rice, M. Wiselka, R. Fox, and D. Pillay. 2001. Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom. J. Clin. Microbiol. 39:2652-2654.
4. Cote, H. C., Z. L. Brumme, and P. R. Harrigan. 2001. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J. Virol. 75:589-594.
5. Gallego, O., C. de Mendoza, A. Corral, and V. Soriano. 2003. Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pre-treated patients. J. Clin. Microbiol. 41:1245-1247.
6. Garcia-Lerma, G., S. Nidtha, K. Blumoff, H. Weinstock, and W. Heneine. 2001. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naïve persons. Proc. Natl. Acad. Sci. USA 98:13907-13912.
7. Gonzalez, L. M. F., R. M. Brindeiro, M. Tarin, A. Calazans, M. A. Soares, S. Cassol, et al. 2003. The subtype C of human immunodeficiency virus type 1 protease presents an in vitro hypersusceptibility to protease inhibitor lopinavir. Antimicrob. Agents Chemother. 47:2117-2122.
8. Hertogs, K., M.-P. De Bethune, V. Miller, T. Ivens, P. Schel, A. Van Cauwenberge, C. Van Den Eynde, V. Van Gerwen, H. Azijn, M. Van Houtte, F. Peeters, S. Staszewski, M. Conant, S. Bloor, S. Kemp, B. Larder, and R. Pauwels. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276.
9. Hirsch, M. S., F. Brun-Vezinet, R. T. D'Aquila, S. M. Hammer, V. A. Johnson, D. R. Kuritzkes, et al. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection. JAMA 283:2417-2426.
10. Holland, J. J., J. C. de la Torre, D. K. Clarke, and E. Duarte. 1991. Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses. J. Virol. 65:2960-2967.
11. Maschera, B., E. Furfine, and E. D. Blair. 1995. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J. Virol. 69:5431-5436.
12. Nicastri, E., L. Sarmati, G. d'Ettorre, L. Palmisano, S. G. Parisi, I. Uccella, A. Rianda, E. Concia, V. Vullo, S. Vella, and M. Andreoni. 2003. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J. Med. Virol. 69:1-6.
13. Palella, F. J., Jr., K. M. Delaney, and A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, and S. D. Holmberg. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
14. Patick, A. K., M. Duran, Y. Cao, D. Shugarts, M. R. Keller, E. Mazabel, M. Knowles, S. Chapman, D. R. Kuritzkes, and M. Markowitz. 1998. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob. Agents Chemother. 42:2637-2644.
15. Perrin, V., and F. Mammano. 2003. Parameters driving the selection of nelfinavir-resistant human immunodeficiency virus type 1 variants. J. Virol. 77:10172-10175.
16. Peters, S., M. Muñoz, S. Yerly, V. Sanchez-Merino, C. Lopez-Galindez, L. Perrin, B. Larder, D. Cmarko, S. Falkan, P. Meylan, and A. Telenti. 2001. Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein. J. Virol. 75:9644-9653.
17. Puchhammer-Stockl, E., C. Kunz, E. Faatz, P. Kasper, F. X. Heinz, et al. 1999. Introduction of HIV-1 subtypes C, E and A into Austria. Clin. Diagn. Virol. 9:25-28.
18. Schinazi, R. F., B. A. Larder, and J. W. Mellors. 2000. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int. Antivir. News 5:65-91.
19. Wu, T. D., C. A. Schiffer, M. J. Gonzales, J. Taylor, R. Kantor, S. Chou, D. Israelski, A. R. Zolopa, W. J. Fessel, and R. W. Shafer. 2003. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J. Virol. 77:4836-4847.
20. Ziermann, R., K. Limoli, K. Das, E. Arnold, C. J. Petropoulos, and N. T. Parkin. 2000. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J. Virol. 74:4414-4419.